Roche Confirms Tocilizumab (Actemra®) Failed to Meet Endpoints in the Phase 3 COVACTA Study Involving COVID-19 Associated Pneumonia

Roche Confirms Tocilizumab (Actemra®) Failed to Meet Endpoints in the Phase 3 COVACTA Study Involving COVID-19 Associated Pneumonia

TrialSite recently suggested based on unfolding study results that repurposed IL-6 inhibitors, such as Roche’s Actemra®/ReActemtra® (tocilizumab), may not work to treat patients infected with COVID-19. TrialSite pointed to the results of an Italian study as a potentially negative signal for the many other studies. Now Roche confirms this with a recent press release declaring that in the COVACTA study the immunosuppressive failed to meet its primary endpoint of improved clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia. Moreover, key secondary endpoints weren’t met either: the IL-6 inhibitor failed to evidence difference in patient mortality at week four.

The COVACTA study revealed at least one positive trend in time to hospital discharge in patients on tocilizumab. The COVACTA study didn’t reveal any new safety signals for Actemra/RoActemra. The company plans on conducting further analysis and will submit the findings for publication in a peer-reviewed journal.

The COVACTA Trial

This clinical trial was conducted in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assista...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee